GlassScriptPhysician profile
Alana M Ryan
NPI 1093166233
$4,291.46
in general payments reported to CMS, 2019-2025
41 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $571 · 2022: $690 · 2023: $190 · 2024: $1,123 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.23 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $880.98 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $415.55 | 2021-2025 | |
| Astellas Pharma US INC | $282.51 | 2024-2025 | Veozah |
| Novo Nordisk INC | $236.97 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $191.20 | 2020-2025 | Otezla, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $180.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.51 | 2020-2025 | Trintellix |
| Axsome Therapeutics, INC. | $142.92 | 2023-2025 | Auvelity, Symbravo |
| Biohaven Pharmaceuticals, INC. | $140.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.33 | 2021-2025 | Jardiance |
| Lundbeck LLC | $113.30 | 2024-2025 | Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $112.97 | 2021-2022 | |
| Lilly USA, LLC | $111.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $88.33 | 2021-2025 | Airsupra, Farxiga |
| Corium, LLC | $84.86 | 2025 | Azstarys |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72.99 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.45 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.99 | 2022-2025 | Xifaxan |
| Cequr Corporation | $60.79 | 2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $58.72 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Neos Therapeutics, LP | $57.59 | 2022-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $56.07 | 2020-2021 | |
| Ardelyx, INC. | $50.42 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $49.93 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $49.86 | 2024-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $45.95 | 2021 | |
| Tris Pharma INC | $44.97 | 2024-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $42.01 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Bausch Health US, LLC | $41.26 | 2025 | Aplenzin |
| Regeneron Healthcare Solutions, INC. | $36.51 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $29.94 | 2025 | Watchman Flx |
| Covis Pharma Gmbh | $26.90 | 2022 | |
| Phadia US INC. | $25.53 | 2024 | Immunocap |
| Hologic Sales and Service, LLC | $22.15 | 2024 | Thinprep 2000 Processor, Aptima |
| Nalu Medical, INC. | $18.43 | 2024 | Nalu Neurostimulation System |
| Exact Sciences Corporation | $17.73 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $17.14 | 2021 | |
| Noven Therapeutics, LLC | $15.96 | 2024 | Xelstrym |
| Biogen, INC. | $13.50 | 2024 | |
| Allergan, INC. | $12.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alana Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.